selective serotonin reuptake inhibitors – A New Vision for Mental Health

Methodological Flaws, Conflicts of Interest, and Scientific Fallacies: Implications for the Evaluation of Antidepressants’ Efficacy and Harm

Author: Editorial 2nd November 2022 0 Comments

This paper by Michael Hengartner has been published in the journal Frontiers in Psychiatry. The abstract says: “Background In current psychiatric practice, antidepressants are widely and with ever-increasing frequency prescribed to patients. However, several scientific biases obfuscate estimates of antidepressants’ efficacy…
Read more

a coherent system

antidepressants, bias, depression, efficacy, evidence-based practice, Frontiers in Psychiatry, harms, Michael Hengartner, Research, selective serotonin reuptake inhibitors, serious adverse events, SSRIs, suicide

Ethical issues in psychopharmacology

Author: Editorial 13th June 2022 0 Comments

This paper by L. McHenry has been published in the Journal of Medical Ethics. The abstract says: “The marketing of selective serotonin reuptake inhibitors in the psychopharmacological industry presents a serious moral problem for the corporate model of medicine. In this…
Read more

a coherent system

antidepressants, ethics, Journal of Medical Ethics, L. McHenry, pharmaceutical industry, psychiatry, psychopharmacology, selective serotonin reuptake inhibitors, SSRI, SSRIs

Let Them Eat Prozac

Author: Editorial 11th January 2019 0 Comments

First published in 2006 and written by psychiatrist David Healy, the full title of this book is Let Them Eat Prozac: The Unhealthy Relationship Between the Pharmaceutical Industry and Depression. The publishers say (within a North American context): “Prozac. Paxil….
Read more

collaborative practice

antidepressants, books, David Healy, depression, Paxil, pharmaceutical industry, Prozac, psychiatry, selective serotonin reuptake inhibitors, SSRI, Zoloft